FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

REGISTER

now for free

Antonio Jimeno

Research Profile

Chemicals & Drugs

Living Beings

Disorders

Concepts & Ideas

Treatment Outcome

Procedures

Anatomy

Tumor Cell Line

Physiology

Register to see full profile

Co-author Network

Register to see all co-authors

Publications

TOP 3
V Narayanan; Daniel A Pollyea; J A Gutman; Antonio Jimeno
Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Hirohiko Kamiyama; Mihoko Kamiyama; Balasubramanyam Karanam; Collins A Karikari; Hong Liang; Ming-Tseh Lin; Jun O Liu; Anirban Maitra; Guanglan Mo; Michael Mullendore; Sherri Rauenzahn; Richard B S Roden; F William Schuler; Joong Sup Shim; Georg Feldmann; Manuel Hidalgo; Ralph Hruban; Li Hua; Elizabeth Jaffee; Antonio Jimeno; H A Jinnah; Robert M Beaty; James R Eshleman
Personalized chemotherapy profiling using cancer cell lines from selectable mice.
S L Davis; S Gail Eckhardt; W A Messersmith; Antonio Jimeno
The development of regorafenib and its current and potential future role in cancer therapy.

Register to see all publications

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Register to see more

Geonetwork of Antonio Jimeno (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Register to see more

All Publications

2013: V Narayanan; Daniel A Pollyea; J A Gutman; Antonio Jimeno
Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Drugs of today (Barcelona, Spain : 1998) 2013;49(4):261-9.
2013: Hirohiko Kamiyama; Mihoko Kamiyama; Balasubramanyam Karanam; Collins A Karikari; Hong Liang; Ming-Tseh Lin; Jun O Liu; Anirban Maitra; Guanglan Mo; Michael Mullendore; Sherri Rauenzahn; Richard B S Roden; F William Schuler; Joong Sup Shim; Georg Feldmann; Manuel Hidalgo; Ralph Hruban; Li Hua; Elizabeth Jaffee; Antonio Jimeno; H A Jinnah; Robert M Beaty; James R Eshleman
Personalized chemotherapy profiling using cancer cell lines from selectable mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(5):1139-46.
2013: S L Davis; S Gail Eckhardt; W A Messersmith; Antonio Jimeno
The development of regorafenib and its current and potential future role in cancer therapy.
Drugs of today (Barcelona, Spain : 1998) 2013;49(2):105-15.
2013: A Dasari; S Diab; H A Drabkin; Thomas W Flaig; Lia Gore; Antonio Jimeno; Karl D Lewis; Wells A Messersmith; C D Weekes; D Ross Camidge
A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.
Investigational new drugs 2013;31(1):115-25.
2012: Daniel Laheru; DUNG LE; Sheila Linden; Florencia McAllister; RAJESH KUMAR NV; MICHELLE RUDEK-RENAUT; Preeti Shah; Dongweon Song; Gretchen Taylor; Ming Zhao; Ross C Donehower; Howard Goldsweig; Antonio Jimeno; Manuel Hidalgo
Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer.
Investigational new drugs 2012;30(6):2391-9.
2012: E R Kessler; E T Lam; D W Bowles; Thomas W Flaig; Antonio Jimeno
Axitinib, a new therapeutic option in renal cell carcinoma.
Drugs of today (Barcelona, Spain : 1998) 2012;48(10):633-44.
2012: David S Hong; Daniel W Bowles; S Gail Eckhardt; Gerald S Falchook; Goldy C George; Diana F Hausman; Roy S Herbst; Kevin Klucher; Razelle Kurzrock; Wells A Messersmith; Cindy L O'Bryant; Scott Peterson; Alex C H Vo; Antonio Jimeno
A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(15):4173-82.
2012: R N Amaria; D W Bowles; Karl D Lewis; Antonio Jimeno
Vismodegib in basal cell carcinoma.
Drugs of today (Barcelona, Spain : 1998) 2012;48(7):459-67.
2012: Daniel W Bowles; D Ross Camidge; Cindy L O'Bryant; Antonio Jimeno
The intersection between cannabis and cancer in the United States.
Critical reviews in oncology/hematology 2012;83(1):1-10.
2012: John J Tentler; Colin D Weekes; John Arcaroli; Antonio Jimeno; Stephen Leong; Wells A Messersmith; Todd M Pitts; Aik Choon Tan; S Gail Eckhardt
Patient-derived tumour xenografts as models for oncology drug development.
Nature reviews. Clinical oncology 2012;9(6):338-50.
2012: Brian L Harry; S Gail Eckhardt; Antonio Jimeno
JAK2 inhibition for the treatment of hematologic and solid malignancies.
Expert opinion on investigational drugs 2012;21(5):637-55.
2012: D W Bowles; R C Doebele; D Ross Camidge; A J Weickhardt; Antonio Jimeno
Crizotinib for the treatment of patients with advanced non-small cell lung cancer.
Drugs of today (Barcelona, Spain : 1998) 2012;48(4):271-82.
2012: R N Amaria; Karl D Lewis; Antonio Jimeno
Vemurafenib: the road to personalized medicine in melanoma.
Drugs of today (Barcelona, Spain : 1998) 2012;48(2):109-18.
2012: Jacob Minor; John Song; Daren Wang; Xiaotian Wang; Xiao-Jing Wang; Fang Zhang; Neil Gross; Antonio Jimeno; Molly Kulesz-Martin; Xian Lu; Shi-Long Lu
Methylation of microRNA-9 is a specific and sensitive biomarker for oral and oropharyngeal squamous cell carcinomas.
Oral oncology 2012;48(1):73-8.
2011: D W Bowles; E R Kessler; Antonio Jimeno
Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).
Drugs of today (Barcelona, Spain : 1998) 2011;47(11):857-68.
2011: Daniel W Bowles; Changhu Chen; David Raben; Krishna Reddy; Alexander Ree; Todd Wine; Antonio Jimeno
Locoregional recurrence of an HPV-positive squamous cell carcinoma of the head and neck.
Oncology (Williston Park, N.Y.) 2011;25(11):1042-8.
2011: Colin D Weekes; Sharyn D Baker; Ross C Donehower; Manuel Hidalgo; Antonio Jimeno; Daniel Laheru; KATHLEEN MURPHY; Sujatha Nallapareddy; Alexis Norris-Kirby; MICHELLE RUDEK-RENAUT; Wells A Messersmith
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.
Investigational new drugs 2011;29(5):1057-65.
2011: Ignacio Garrido-Laguna; Elizabeth de Oliveira; Ralph Hruban; Antonio Jimeno; Collins A Karikari; Daniel Laheru; Anirban Maitra; RAJESH KUMAR NV; Belen Rubio-Viqueira; Ana Salomon; Rajni Sharma; Aik Choon Tan; Gretchen Taylor; Maria Uson; Maria C Villaroel; Manuel Hidalgo
Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(17):5793-800.
2011: Daniel W Bowles; Antonio Jimeno
New phosphatidylinositol 3-kinase inhibitors for cancer.
Expert opinion on investigational drugs 2011;20(4):507-18.
2011: Cristina Grávalos; Carlos Gómez-Martín; Fernando Rivera; Inmaculada Alés; Bernardo Queralt; Antonia Márquez; Ulpiano Jiménez; Vicente Alonso; Rocío García-Carbonero; Javier Sastre; ramon colomer; Hernán Cortés-Funes; Antonio Jimeno
Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2011;13(3):179-84.
2010: Wells A Messersmith; Antonio Jimeno; Heather A Jacene; Ming Zhao; Piotr Kulesza; Daniel Laheru; Yasmin Kahn; Alexander Spira; Janet Dancey; Christine A Iacobuzio-Donahue; Ross C Donehower; Michael A Carducci; MICHELLE RUDEK-RENAUT; Manuel Hidalgo
Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer.
Clinical colorectal cancer 2010;9(5):297-304.
2010: Kyle E Rusthoven; Steven Feigenberg; David Raben; Madeleine Kane; John I Song; Nicos Nicolaou; Ranee Mehra; Barbara Burtness; John Ridge; Robyn Swing; Miriam Lango; Roger Cohen; Antonio Jimeno; Changhu Chen
Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer.
International journal of radiation oncology, biology, physics 2010;78(4):1020-5.
2010: Stephen B Keysar; Antonio Jimeno
More than markers: biological significance of cancer stem cell-defining molecules.
Molecular cancer therapeutics 2010;9(9):2450-7.
2010: I Garrido-Laguna; Aik Choon Tan; M Uson; M Angenendt; Wen W Ma; M C Villaroel; Ming Zhao; RAJESH KUMAR NV; Antonio Jimeno; Ross C Donehower; Christine A Iacobuzio-Donahue; M Barrett; MICHELLE RUDEK-RENAUT; Belen Rubio-Viqueira; Daniel Laheru; Manuel Hidalgo
Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.
British journal of cancer 2010;103(5):649-55.
2010: Cristina Gravalos; Javier Cassinello; Pilar García-Alfonso; Antonio Jimeno
Integration of panitumumab into the treatment of colorectal cancer.
Critical reviews in oncology/hematology 2010;74(1):16-26.
2010: Zeshaan A Rasheed; Jie Yang; Qiuju Wang; Jeanne Kowalski; Irwin Freed; Christopher Murter; Seung-Mo Hong; Jan-Bart Koorstra; RAJESH KUMAR NV; Xiaobing He; Michael Goggins; Christine A Iacobuzio-Donahue; berman david; Daniel Laheru; Antonio Jimeno; Manuel Hidalgo; Anirban Maitra; William Matsui
Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma.
Journal of the National Cancer Institute 2010;102(5):340-51.
2010: Antonio Jimeno; Belen Rubio-Viqueira; RAJESH KUMAR NV; Audrey Chan; Anna Solomon; Manuel Hidalgo
A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer.
Molecular cancer therapeutics 2010;9(2):311-8.
2010: Wen Wee Ma; JOSEPH HERMAN; Antonio Jimeno; Daniel Laheru; Wells A Messersmith; Christopher L Wolfgang; John L Cameron; Timothy M Pawlik; Ross C Donehower; MICHELLE RUDEK-RENAUT; Manuel Hidalgo
A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer.
Translational oncology 2010;3(6):373-9.
2010: Wilbur A Franklin; Jerry Haney; Michio Sugita; Lynne Bemis; Antonio Jimeno; Wells A Messersmith
KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer.
The Journal of molecular diagnostics : JMD 2010;12(1):43-50.
2009: Jennifer R Diamond; Virginia F Borges; S Gail Eckhardt; Antonio Jimeno
BRCA in breast cancer: from risk assessment to therapeutic prediction.
Drug news & perspectives 2009;22(10):603-8.
2009: Aik Choon Tan; Antonio Jimeno; Steven H Lin; Jenna Wheelhouse; Fonda Chan; Anna Solomon; RAJESH KUMAR NV; Belen Rubio-Viqueira; Manuel Hidalgo
Characterizing DNA methylation patterns in pancreatic cancer genome.
Molecular oncology 2009;3(5-6):425-38.
2009: Maria Cristina Villarroel; Manuel Hidalgo; Antonio Jimeno
Mycophenolate mofetil: An update.
Drugs of today (Barcelona, Spain : 1998) 2009;45(7):521-32.
2009: RAJESH KUMAR NV; Aik Choon Tan; Elizabeth De Oliveira; Chris Womack; Helen Wombwell; Shethah Morgan; Madhuri V Warren; Jill Walker; Tim P Green; Antonio Jimeno; Wells A Messersmith; Manuel Hidalgo
Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(12):4138-46.
2009: Wells A Messersmith; RAJESH KUMAR NV; Aik Choon Tan; Xiao Fei Wang; Veronica Diesl; Sung E Choe; Max Follettie; Christina Coughlin; Frank Boschelli; Elena Garcia-Garcia; Fernando Lopez-Rios; Antonio Jimeno; Manuel Hidalgo
Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts.
Molecular cancer therapeutics 2009;8(6):1484-93.
2009: Wen Wee Ma; Heather A Jacene; Dongweon Song; Felip Vilardell; Wells A Messersmith; Daniel Laheru; Richard L Wahl; Christopher J Endres; Antonio Jimeno; Martin G Pomper; Manuel Hidalgo
[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(16):2697-704.
2009: Antonio Jimeno; Wells A Messersmith; Fred R Hirsch; Wilbur A Franklin; S Gail Eckhardt
KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer.
Cancer journal (Sudbury, Mass.) 2009;15(2):110-3.
2009: Shabana Shabbeer; Michelle Sobolewski; RAVI ANCHOORI; Sushant Kachhap; Manuel Hidalgo; Antonio Jimeno; Nancy E Davidson; Michael A Carducci; Saeed R Khan
Fenugreek: a naturally occurring edible spice as an anticancer agent.
Cancer biology & therapy 2009;8(3):272-8.
2009: Antonio Jimeno; Georg Feldmann; Ana Suárez-Gauthier; Zeshaan Rasheed; Anna Solomon; Gang-Ming Zou; Belen Rubio-Viqueira; Elena García-García; Fernando López-Ríos; William Matsui; Anirban Maitra; Manuel Hidalgo
A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development.
Molecular cancer therapeutics 2009;8(2):310-4.
2008: Dongweon Song; Raghothama Chaerkady; Aik Choon Tan; Elena García-García; Anuradha Nalli; Ana Suárez-Gauthier; Fernando López-Ríos; Xian Feng Zhang; Anna Solomon; Jeffrey Tong; Margaret Read; Christian Fritz; Antonio Jimeno; Akhilesh Pandey; Manuel Hidalgo
Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer.
Molecular cancer therapeutics 2008;7(10):3275-84.
2008: Daniel Laheru; Gary Croghan; Ronald Bukowski; MICHELLE RUDEK-RENAUT; Wells A Messersmith; Charles Erlichman; Robert Pelley; Antonio Jimeno; Ross C Donehower; Joseph Boni; Richat Abbas; Patricia Martins; Charles Zacharchuk; Manuel Hidalgo
A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(17):5602-9.
2008: Antonio Jimeno; MICHELLE RUDEK-RENAUT; Peter Kulesza; Wen W Ma; Jenna Wheelhouse; Anna Howard; Yasmin Khan; Ming Zhao; Heather A Jacene; Wells A Messersmith; Daniel Laheru; Ross C Donehower; Elizabeth Garrett-Mayer; Sharyn D Baker; Manuel Hidalgo
Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(25):4172-9.
2008: Cristina Gravalos; Antonio Jimeno
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(9):1523-9.
2008: Antonio Jimeno; Aik Choon Tan; Jordy Coffa; RAJESH KUMAR NV; Piotr Kulesza; Belen Rubio-Viqueira; Jenna Wheelhouse; Begoña Diosdado; Wells A Messersmith; Christine A Iacobuzio-Donahue; Anirban Maitra; Marileila Varella-Garcia; Fred R Hirsch; Gerrit A Meijer; Manuel Hidalgo
Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer.
Cancer research 2008;68(8):2841-9.
2008: Antonio Jimeno; MICHELLE RUDEK-RENAUT; W. PURCELL; Daniel Laheru; Wells A Messersmith; Janet Dancey; Michael A Carducci; Sharyn D Baker; Manuel Hidalgo; Ross C Donehower
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
Cancer chemotherapy and pharmacology 2008;61(3):423-33.
2008: Antonio Jimeno; Wells A Messersmith; Carlton K K Lee; Wen W Ma; Daniel Laheru; Ross C Donehower; Sharyn D Baker; Manuel Hidalgo
Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(2):374-9.
2008: Antonio Jimeno; C Grávalos; Pilar Escudero; I Sevilla; M E Vega-Villegas; Vicente Alonso; I Juez; Rocío García-Carbonero; H Bovio; ramon colomer; Hernán Cortés-Funes
Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2008;10(1):52-7.
2007: Wen W Ma; Antonio Jimeno
Temsirolimus.
Drugs of today (Barcelona, Spain : 1998) 2007;43(10):659-69.
2007: Jing Li; Ming Zhao; Antonio Jimeno; Ping He; M V Ramana Reddy; Manuel Hidalgo; Ross C Donehower; MICHELLE RUDEK-RENAUT
Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2007;856(1-2):198-204.
2007: Antonio Jimeno; Najat C Daw; Maria L Amador; George Cusatis; Piotr Kulesza; Mark Krailo; Ashish Ingle; Susan M Blaney; Peter Charles Adamson; Manuel Hidalgo
Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors.
Pediatric blood & cancer 2007;49(3):352-7.
2007: Antonio Jimeno; Gurulingappa Hallur; Audrey Chan; Xiangfeng Zhang; George Cusatis; Fonda Chan; Preeti Shah; Rongbing Chen; Ernest Hamel; Elizabeth Garrett-Mayer; Saeed R Khan; Manuel Hidalgo
Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer.
Molecular cancer therapeutics 2007;6(5):1509-16.
2007: Wen W Ma; Antonio Jimeno
Strategies for suppressing angiogenesis in gynecological cancers.
Drugs of today (Barcelona, Spain : 1998) 2007;43(4):259-73.
2007: Antonio Jimeno; Piotr Kulesza; J Wheelhouse; A Chan; X Zhang; Erik Kincaid; R Chen; Douglas P Clark; Arlene A Forastiere; Manuel Hidalgo
Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy.
British journal of cancer 2007;96(6):952-9.
2007: Antonio Jimeno; Belen Rubio-Viqueira; Maria L Amador; Victor Grunwald; Anirban Maitra; Christine A Iacobuzio-Donahue; Manuel Hidalgo
Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer.
Molecular cancer therapeutics 2007;6(3):1079-88.
2007: Georg Feldmann; Surajit Dhara; Volker Fendrich; Djahida Bedja; ROBERT BEATY; Michael Mullendore; Collins A Karikari; Hector Alvarez; Christine A Iacobuzio-Donahue; Antonio Jimeno; Kathleen L Gabrielson; William Matsui; Anirban Maitra
Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers.
Cancer research 2007;67(5):2187-96.
2007: Belen Rubio-Viqueira; Heather Mezzadra; Matthew Nielsen; Antonio Jimeno; Xianfeng Zhang; Christine A Iacobuzio-Donahue; Anirban Maitra; Manuel Hidalgo; Soner Altiok
Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays.
Molecular cancer therapeutics 2007;6(2):515-23.
2006: Antonio Jimeno; Maria L Amador; Piotr Kulesza; Xiaofei Wang; Belen Rubio-Viqueira; Xiangfeng Zhang; Audrey Chan; Jenna Wheelhouse; Hidekazu Kuramochi; Koji Tanaka; Kathleen Danenberg; Wells A Messersmith; Virna Almuete; Ralph Hruban; Anirban Maitra; Charles J Yeo; Manuel Hidalgo
Assessment of celecoxib pharmacodynamics in pancreatic cancer.
Molecular cancer therapeutics 2006;5(12):3240-7.
2006: Antonio Jimeno; Alberto Arcediano; S Bazares; Maria L Amador; L González-Cortijo; Eva Ciruelos; L Robles; Daniel Castellano; Luis Paz-Ares; Carlos Lumbreras; Javier Hornedo; Hernán Cortés-Funes
Randomized study of cefepime versus ceftazidime plus amikacin in patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS) with febrile neutropenia.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2006;8(12):889-95.
2006: Antonio Jimeno; Manuel Hidalgo
Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.
Biochimica et biophysica acta 2006;1766(2):217-29.
2006: Michael A Carducci; Antonio Jimeno
Targeting bone metastasis in prostate cancer with endothelin receptor antagonists.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(20 Pt 2):6296s-6300s.
2006: Belen Rubio-Viqueira; Antonio Jimeno; George Cusatis; Xianfeng Zhang; Christine A Iacobuzio-Donahue; Collins A Karikari; Chanjuan Shi; Kathleen Danenberg; Peter V Danenberg; Hidekazu Kuramochi; Koji Tanaka; Sharat Singh; Hossein Salimi-Moosavi; Nadia Bouraoud; Maria L Amador; Soner Altiok; Piotr Kulesza; Charles Yeo; Wells A Messersmith; James R Eshleman; Ralph Hruban; Anirban Maitra; Manuel Hidalgo
An in vivo platform for translational drug development in pancreatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(15):4652-61.
2006: Miguel Quintela-Fandino; Joaquín Martínez López; Ricardo Hitt; Soledad Gamarra; Antonio Jimeno; ROSA AYALA; Javier Hornedo; Cecilia Guzman; Florinda Gilsanz; Hernán Cortés-Funes
Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(22):3611-8.
2006: Antonio Jimeno; Manuel Hidalgo
Multitargeted therapy: can promiscuity be praised in an era of political correctness?
Critical reviews in oncology/hematology 2006;59(2):150-8.
2006: Manuel Hidalgo; Maria L Amador; Antonio Jimeno; Heather Mezzadra; Pina Patel; Audrey Chan; Matthew Nielsen; Anirban Maitra; Soner Altiok
Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration.
Molecular cancer therapeutics 2006;5(7):1895-903.
2006: Antonio Jimeno; Michael A Carducci
Atrasentan: a rationally designed targeted therapy for cancer.
Drugs of today (Barcelona, Spain : 1998) 2006;42(5):299-312.
2006: Gurulingappa Hallur; Antonio Jimeno; Susan L Dalrymple; Tao Zhu; M Katherine Jung; Manuel Hidalgo; John T Isaacs; Saraswati Sukumar; Ernest Hamel; Saeed R Khan
Benzoylphenylurea sulfur analogues with potent antitumor activity.
Journal of medicinal chemistry 2006;49(7):2357-60.
2006: Antonio Jimeno; Manuel Hidalgo
Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer.
Molecular cancer therapeutics 2006;5(4):787-96.
2006: Antonio Jimeno; Piotr Kulesza; Erik Kincaid; Nadia Bouaroud; Audrey Chan; Arlene A Forastiere; Julie R Brahmer; Douglas P Clark; Manuel Hidalgo
C-fos assessment as a marker of anti-epidermal growth factor receptor effect.
Cancer research 2006;66(4):2385-90.
2006: Ricardo Hitt; Maria L Amador; Miguel Quintela-Fandino; Antonio Jimeno; Olga del Val; Susana Hernando; Hernán Cortes-Funes
Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Cancer 2006;106(1):106-11.
2005: MICHELLE RUDEK-RENAUT; Ming Zhao; Nicola F Smith; Robert W Robey; Ping He; Gurulingappa Hallur; Saeed R Khan; Manuel Hidalgo; Antonio Jimeno; A Dimitrios Colevas; Wells A Messersmith; Antonio C Wolff; Sharyn D Baker
In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(23):8503-11.
2005: Wells A Messersmith; Darin Oppenheimer; Josep Peralba; Valeria Sebastiani; Maria Amador; Antonio Jimeno; Erlinda Embuscado; Manuel Hidalgo; Christine A Iacobuzio-Donahue
Assessment of Epidermal Growth Factor Receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis.
Cancer biology & therapy 2005;4(12):1381-6.
2005: Antonio Jimeno; Manuel Hidalgo
Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity.
Expert review of anticancer therapy 2005;5(4):727-35.
2005: Antonio Jimeno; Teresa Toledo; Ignacio Moya; Antonio González-Barber
Chronic disseminated intravascular coagulation caused by an aorto-bifemoral aneurysm.
European journal of internal medicine 2005;16(4):298-300.
2005: Antonio Jimeno; Michael A Carducci
Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer.
Expert review of anticancer therapy 2005;5(3):419-27.
2005: Ming Zhao; Carol Hartke; Antonio Jimeno; Jing Li; Ping He; Yelena Zabelina; Manuel Hidalgo; Sharyn D Baker
Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2005;819(1):73-80.
2005: Antonio Jimeno; Belen Rubio-Viqueira; Maria L Amador; Darin Oppenheimer; Nadia Bouraoud; Piotr Kulesza; Valeria Sebastiani; Anirban Maitra; Manuel Hidalgo
Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents.
Cancer research 2005;65(8):3003-10.
2005: Antonio Jimeno
Race, gender and mutations in the prediction of anti-EGFR activity.
Future oncology (London, England) 2005;1(2):201-4.
2005: Antonio Jimeno; Manuel Hidalgo
Blockade of epidermal growth factor receptor (EGFR) activity.
Critical reviews in oncology/hematology 2005;53(3):179-92.
2005: Antonio Jimeno; Ricardo Hitt; Miguel Quintela-Fandino; Hernán Cortés-Funes
Phase II trial of vinorelbine tartrate in patients with treatment-naive metastatic melanoma.
Anti-cancer drugs 2005;16(1):53-7.
2004: Ricardo Hitt; Antonio Jimeno; M Rodríguez-Pinilla; José L Rodríguez-Peralto; Jose Millan; Ana López-Martín; A Brandariz; C Peña; Hernán Cortés-Funes
Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors.
British journal of cancer 2004;91(12):2005-11.
2004: Antonio Jimeno; Michael A Carducci
Atrasentan: targeting the endothelin axis in prostate cancer.
Expert opinion on investigational drugs 2004;13(12):1631-40.
2004: Ricardo Hitt; Antonio Jimeno; Jose Millan; Daniel Castellano; Hernán Cortés-Funes
Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck.
Cancer 2004;101(4):768-75.
2004: Maria L Amador; Antonio Jimeno; Ricardo Hitt; Hernán Cortés-Funes; ramon colomer
Dose and dose intensity effect of adjuvant anthracycline-based chemotherapy in early breast cancer: a retrospective analysis.
American journal of clinical oncology 2004;27(3):269-73.
2004: Antonio Jimeno; Adelaida García-Velasco; Olga del Val; Enrique González-Billalabeitia; Susana Hernando; Rosario Hernández; Alfonso Sánchez-Muñoz; Ana López-Martín; Ignacio Durán; Luis Robles; Hernán Cortés-Funes; Luis Paz-Ares
Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia.
Cancer 2004;100(11):2462-9.
2004: Antonio Jimeno; Maria L Amador; Lucía González-Cortijo; María Victoria Tornamira; Santiago Ropero; Vicente Valentín; Javier Hornedo; Hernán Cortés-Funes; ramon colomer
Initially metastatic breast carcinoma has a distinct disease pattern but an equivalent outcome compared with recurrent metastatic breast carcinoma.
Cancer 2004;100(9):1833-42.
2003: Ricardo Hitt; Antonio Jimeno; Daniel Castellano; Hernán Cortés-Funes
Unusual response to gemcitabine in a case of peritoneal malignant fibrous histiocytoma.
Anti-cancer drugs 2003;14(8):663-4.
2003: Antonio Jimeno; Eva M Ciruelos; Daniel Castellano; Begoña Caballero; Jose Luis Rodriguez-Peralto; Hernán Cortés-Funes
Radiation recall dermatitis induced by pegylated liposomal doxorubicin.
Anti-cancer drugs 2003;14(7):575-6.

Register to see more

Copyright © 2011 Elsevier Inc. All rights reserved.